Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 4/20 | 0.39 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3062712 | 0.79 | TSHR (0.42) | LMNAALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL3072447 | 0.74 | CYP1A2 (0.46) | LMNAPPARGPPARAKMT2AMEN1 | |
| SCHEMBL3072451 | 0.74 | CYP1A2 (0.46) | LMNAPPARGPPARAKMT2AMEN1 | |
| SCHEMBL5693245 | 0.74 | CYP1A2 (0.46) | LMNAPPARGPPARAKMT2AMEN1 | |
| SCHEMBL3053051 | 0.74 | CYP1A2 (0.46) | LMNAPPARGPPARAKMT2AMEN1 | |
| SCHEMBL3053052 | 0.74 | CYP1A2 (0.46) | LMNAPPARGPPARAKMT2AMEN1 | |
| SCHEMBL11699833 | 0.74 | LMNA (0.55) | LMNAALDH1A1PPARGPPARAKMT2A | |
| SCHEMBL7638637 | 0.74 | LMNA (0.55) | LMNAALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL8124029 | 0.72 | LMNA (0.53) | LMNAALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL11404629 | 0.72 | DEGS1 (0.41) | LMNAALDH1A1KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261789-A1 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | ZEILLER JEAN-JACQUES | 2010-10-14 | — | — | US | claimed |
| US-20060178434-A1 | Butenoic acid derivatives processes for the preparation thereof pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2006-08-10 | — | — | US | claimed |
| US-8247448-B2 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2012-08-21 | — | — | US | disclosed |
| US-7820847-B2 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20100261789-A1 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | ZEILLER JEAN-JACQUES | 2010-10-14 | — | — | US | disclosed |
| US-20060178434-A1 | Butenoic acid derivatives processes for the preparation thereof pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261789-A1 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | ALOX15, LIPA, APOB | LMNA 383/4885ALDH1A1 580/4885PPARG 130/4885 |
| US-20060178434-A1 | Butenoic acid derivatives processes for the preparation thereof pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia atherosclerosis and diabetes | APOB, ALOX15, GPR119 | LMNA 394/4885ALDH1A1 647/4885PPARG 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.